Rita Barcia

Company: SIRPant Immunotherapeutics
Job title: Vice President, Process Development & Operations
Seminars:
A Novel Approach to Cancer-Agnostic Treatment of Tumors With Non-Genetically Modified Macrophages 2:00 pm
SIRpant uses a non-genetic approach to reprogramming macrophages that removes SIRPɑ and simultaneously reprograms them to promote an anti-cancer response whilst reducing manufacturing time Our macrophages act by directly attacking cancerous cells, stimulating cancer neoantigen-specific cytotoxic T cells and antibodies, reducing immunosuppressive elements, and perpetuating a pro-inflammatory TME that favors cancer elimination Overcoming manufacturing challenges…Read more
day: Day One Track A PM